AWARDS & RECOGNITION

Krishna has long been recognized as a leading advisor by numerous industry publications and directories, including Chambers USA and
The Legal 500. He has been named a “Dealmaker of the Year” by The American Lawyer (2018, 2022); a “Mergers & Acquisitions MVP” by Law360 (2022); one of the “500 Leading Lawyers in America” (2021, 2022) and one of the “500 Leading Dealmakers in America” by Lawdragon (2021, 2022); “Healthcare Trailblazer” by The National Law Journal (2019); a “Retail & E-Commerce MVP” by Law360 (2017); a “Life Sciences MVP” by Law360 (2015, 2016, 2023); a “Transatlantic Rising Star” by The American Lawyer (2016); a “Dealmaker of the Week” by The American Lawyer (2014, 2015); a “Rising Star” by Law360 (2014, 2015) and New York Law Journal (2015); and a “Highly Regarded Lawyer” by IFLR1000. Krishna was listed as one of the “Best Lawyers Under 40” by the National Asian Pacific American Bar Association (2014), and was named one of four “Rising Stars” by the Minority Corporate Counsel Association (2013).

EXPERIENCE

Krishna’s M&A experience spans a broad range of industries. Notable representations have included:

CONSUMER & RETAIL / INDUSTRIALS 

• General Electric in its reorganization through spin-offs into separate publicly traded aviation, healthcare and energy companies
• AB InBev in its $123 billion merger with SABMiller and in its $20.1 billion acquisition of the remaining stake it didn't already own in Grupo Modelo
• Praxair in its $80 billion merger with Linde
• Amazon.com in its $13.7 billion acquisition of Whole Foods and its $3.9 billion acquisition of One Medical
• General Cable in its $3 billion sale to Prysmian Group
• The Estée Lauder Companies in its $2.8 billion acquisition of the Tom Ford brand
• Standard Industries in its $2.1 billion acquisition of Braas Monier; $1.1 billion acquisition of Icopal; and acquisition of Quest Construction Products
• Lion Capital in its affiliate’s DIP financing for and acquisition of John Varvatos Enterprises in a Section 363 sale process; acquisition of a minority interest in Authentic Brands; acquisition of Spence Diamonds; and proposed $1.5 billion sale of Bumble Bee Foods to Thai Union Frozen Products
• The special committee of the board of directors of Madison Square Garden Entertainment in the spin-off of its traditional live entertainment businesses, to create a new publicly traded company known as Sphere Entertainment Co.
• Flexpoint Ford in its acquisition of Baker Hill Solutions
• Sir Jim Ratcliffe’s investment vehicle, Trawlers Limited, on its investment in Manchester United

TECHNOLOGY

• Special Committee of Solera Holdings in its $6.5 billion sale to Vista Equity Partners
• Qualcomm, alongside SSW Partners, in its $4.5 billion topping bid for Veoneer
• Special Committee of QAD in its $2 billion sale to Thoma Bravo
• Amazon.com in its proposed $1.4 billion acquisition of iRobot and in its agreement to utilize Plug Power fuel cells and hydrogen technology in its fulfillment network
• Unisys in its $1.2 billion sale of its U.S. Federal business to Science Applications International Corporation (SAIC)
• Broadcom in its sale of certain assets and manufacturing rights associated with its wireless IoT business to Synaptics
• Digital Currency Group in the sale of CoinDesk to Bullish
• Genesis Robotics in its sale of a controlling stake to Koch Chemical Technology Group
• Marathon Digital Holdings in its acquisition of two operational Bitcoin mining sites from subsidiaries of Generate Capital
• SEAKR Engineering in its sale to Raytheon Technologies

HEALTHCARE & LIFE SCIENCES

• Teva in its $40.5 billion acquisition of Allergan Generics and $50.5 billion unsolicited proposal for Mylan, later withdrawn
• PRA Health Sciences in its approximately $12 billion sale to ICON
• Stemcentrx in its $9.8 billion sale to AbbVie
• Synageva in its $8.4 billion sale to Alexion
• Syneos Health in its $7.4 billion merger of equals with inVentiv Health
• Dyax in its $5.9 billion sale to Shire
• Concordia Healthcare in its $3.5 billion acquisition of Amdipharm Mercury and $1.2 billion acquisition of all commercial assets of Covis
• Amedisys in its $3.3 billion combination with Optum
• Translate Bio in its $3.2 billion sale to Sanofi
• Inhibrx in the $2.2 billion sale of INBRX-101 to Sanofi and the related spin-off of Inhibrx's non-101 assets and liabilities, non-101 discovery pipeline and its corporate infrastructure, to create a new publicly traded company known as Inhibrx Biosciences
• GSK in its $2 billion acquisition of BELLUS Health and its up-to-$50 million acquisition of Elsie Biotechnologies
• Apple Tree Partners as the majority shareholder in Syntimmune, in Syntimmune’s up to $1.2 billion sale to Alexion Pharmaceuticals
• Seattle Genetics in its $614 million acquisition of Cascadian Therapeutics
• Aurobindo Pharma USA in its $550 million sale of Natrol to an affiliate of New Mountain Capital to combine with Jarrow Formulas
• Casdin Capital, alongside Viking Global Investors, in the $250 million investment in Fluidigm Corporation
• AbbVie in its up to $212.5 million acquisition of Landos Biopharma
• Albireo in a $115 million royalty monetization agreement with Sagard Healthcare Partners and in its up to $1.3 billion sale to Ipsen
• Blackstone in connection with Precision Medicine Group’s major investment and recapitalization
• Exelixis in its proxy contest against Farallon Capital Partners

ENERGY

• Endeavor Energy Resources in its $26 billion merger with Diamondback Energy
• Concho Resources in its $13 billion acquisition by ConocoPhillips and $9.5 billion acquisition of RSP Permian
• John Wood Group in its $1.9 billion sale of its Built Environment consulting business to WSP Global
• Andeavor in the merger of Andeavor Logistics and Western Refining Logistics for $1.8 billion and the repositioning of Andeavor Logistics through an IDR buy-in valued at $4 billion
• Cheniere Energy in its acquisition of the publicly-held shares of Cheniere Energy Partners LP Holdings not already owned by Cheniere
• Peabody Energy in its agreement with Elliott Management providing for the addition of four new directors to Peabody’s board

REAL ESTATE

• Forest City Realty Trust in its $11.4 billion sale to Brookfield Asset Management and agreement with Starboard Value to reconstitute its board of directors, in connection with the company's agreement to declassify its common stock and its settlement with Scopia Capital
• American Casino & Entertainment Properties in its $850 million sale to Golden Entertainment

Krishna is involved in numerous professional, academic and community organizations. He is a member of the Council on Foreign Relations, the Dean’s Advisory Council of Princeton University, the Board of Trustees at Ethical Culture Fieldston School, Board of Directors of South Asian Youth Action, and the Steering Committee of the Board of Visitors at Columbia Law School, where he is also an adjunct professor. In 2014, the New York State Bar Association named him an Empire State Counsel Honoree for Pro bono Service.

Krishna is a frequent speaker and writer on developments in M&A and shareholder activism, as well as on law firm diversity strategies. He has been quoted in numerous articles in business and legal publications.